Hydroa vacciniforme-like Epstein-Barr virus-associated monoclonal T-lymphoproliferative disorder in a child

International Journal of Dermatology

Volumn 46, Issue 10, 2007, Pages 1081-1086

  Wu, Yu Hung ^a   Chen, Hsiu Chin ^a,b   Hsiao, Pa Fan ^a   Tu, Mei Ing ^a   Lin, Yang Chih ^a   Wang, Tao Yuan ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID;

ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CHRONIC HEPATITIS; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DIFFERENTIAL DIAGNOSIS; EPSTEIN BARR VIRUS; FOLLOW UP; GENE REARRANGEMENT; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MALE; PRESCHOOL CHILD; RASH; SKIN BIOPSY; SKIN MANIFESTATION; T LYMPHOCYTE RECEPTOR GENE; VASCULITIS; VIRUS INFECTION;

ANTIGENS, CD; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; GENE REARRANGEMENT, GAMMA-CHAIN T-CELL ANTIGEN RECEPTOR; HERPESVIRUS 4, HUMAN; HUMANS; HYDROA VACCINIFORME; LYMPHOPROLIFERATIVE DISORDERS; MALE; POLYMERASE CHAIN REACTION; SKIN; T-LYMPHOCYTES;

EID: 34848832699     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.03102.x     Document Type: Article

References (31)

1. Gupta G, Man I, Kemmett D. Hydroa vacciniforme: A clinical and follow-up study of 17 cases. J Am Acad Dermatol 2000; 42: 208-213.
2. Oono T, Arata J, Masuda T, et al. Coexistence of hydroa vacciniforme and malignant lymphoma. Arch Dermatol 1986; 122: 1306-1309.
3. Tabata N, Aiba S, Ichinohazama R, et al. Hydroa vacciniforme-like lymphomatoid papulosis in a Japanese child: A new subset. J Am Acad Dermatol 1995; 32: 378-381.
4. Magana M, Sangueza P, Gil-Beristain J, et al. Angiocentric cutaneous T-cell lymphoma of childhood (hydroa-like lymphoma): A distinctive type of cutaneous T-cell lymphoma. J Am Acad Dermatol 1998; 38: 574-579.
5. Iwatsuki K, Ohtsuka M, Akiba H, et al. Atypical hydroa vacciniforme in childhood: From a smoldering stage to Epstein-Barr virus-associated lymphoid malignancy. J Am Acad Dermatol 1999; 40: 283-284.
6. Cho KH, Kim CW, Heo DS, et al. Epstein-Barr virus-associated peripheral T-cell lymphoma in adults with hydroa vacciniforme-like lesions. Clin Exp Dermatol 2001; 26: 242-247.
7. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma: A clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morph 2002; 10: 7-14.
8. Cho KH, Lee SH, Kim CW, et al. Epstein-Barr virus-associated lymphoproliferative lesions presenting as a hydroa vacciniforme-like eruption: An analysis of six cases. Br J Dermatol 2004; 151: 372-380.
9. Iwatsuki K, Xu Z, Takata M, et al. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol 1999; 140: 715-721.
10. Ohtsuka T, Okita H, Otsuka S, et al. Hydroa vacciniforme with latent Epstein-Barr virus infection. Br J Dermatol 2001; 145: 509-510.
11. Heo EP, Park SH, Kim TH. Artificial reproduction of atypical hydroa vacciniforme caused by latent Epstein-Barr virus infection. Int J Dermatol 2003; 42: 476-479.
12. Katagiri Y, Mitsuhashi Y, Kondo S, et al. Hydroa vacciniforme-like eruptions in a patient with chronic active EB virus infection. J Dermatol 2003; 30: 400-404.
13. Catherine T, Sandrine G, Severine V, et al. PCR analysis of immunoglobulin heavy chain (IgH) and TcR-γ chain gene rearrangements in the diagnosis of lymphoproliferative disorders: results of a study of 525 cases. Mod Pathol 2000; 13: 1269-1279.
14. Goldgeier MH, Nordlund JJ, Lucky AW, et al. Hydroa vacciniforme: diagnosis and therapy. Arch Dermatol 1982; 118: 588-591.
15. Sonnex TS, Hawk JL. Hydroa vacciniforme: A review of ten cases. Br J Dermatol 1988; 118: 101-108.
16. Ruiz-Maldonado R, Parrilla FM, Orozco-Covarrubias ML, et al. Edematous, scarring vasculitic panniculitis: A new multisystemic disease with malignant potential. J Am Acad Dermatol 1995; 32: 37-44.
17. Chen HH, Hsiao CH, Chiu HC. Hydroa vacciniforme-like primary cutaneous CD8-positive T-cell lymphoma. Br J Dermatol 2002; 147: 587-591.
18. Iwatsuki K, Ohtsuka M, Harada H, et al. Clinicopathologic manifestations of Epstein-Barr virus-associated cutaneous lymphoproliferative disorders. Arch Dermatol 1997; 133: 1081-1086.
19. Chan A, Ho J, Chiang A, et al. Phenotypic and cytotoxic characteristics of peripheral T-cell and NK-cell lymphomas in relation to Epstein-Barr virus association. Histopathology 1999; 34: 16-24.
20. Zaunders JJ, Munier ML, Kaufmann DE et al. Early proliferation of CCR5+ CD38+++ antigen-specific CD4+ Th1 effector cells during primary HIV-1 infection. Blood 2001; 106: 1660-1667.
21. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-492.
22. Klein G. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 1994; 77: 791-793.
23. Maia DM, Peace-Brewer AL. Chronic, active Epstein-Barr virus infection. Curr Opin Hematol 2000; 7: 59-63.
24. Okano M. Overview and problematic standpoints of severe chronic active Epstein-Barr virus infection syndrome. Crit Rev Oncol Hematol 2002; 44: 273-282.
25. Niedobitek G, Meru N, Delecluse HJ. Epstein-Barr virus infection and human malignancies. Int J Exp Pathol 2001; 82: 149-170.
26. Yachie A, Kanegane H, Kasahara Y. Epstein-Barr virus-associated T-/ natural killer cell lymphoproliferative diseases. Semin Hematol 2003; 40: 124-132.
27. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001; 98: 280-286.
28. Tokura Y, Ishihara S, Tagawa S, et al. Hypersensitivity to mosquito bites as the primary clinical manifestation of a juvenile type of Epstein-Barr virus-associated natural killer cell leukemia/lymphoma. J Am Acad Dermatol 2001; 45: 569-578.
29. Kase S, Adachi H, Osaki M, et al. Epstein-Barr virus-infected malignant T/NK-cell lymphoma in a patient with hypersensitivity to mosquito bites. Int J Surg Pathol 2004; 12: 265-272.
30. Kimura H, Hoshino Y, Hara S, et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis 2005; 4: 531-539.
31. Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 2003; 187: 527-533.